A型肉毒毒素电子微滴注射治疗红斑毛细血管扩张型玫瑰痤疮的临床观察OA

Objective To explore the clinical efficacy and safety of electro-hydrodynamic droplet injection of botulinum toxin type A(BTX-A)for the treatment of erythematotelangiectatic rosacea(ETR).Methods Twenty-seven females with ETR were treated with electro-hydrody-namic droplet injection of BTX-A at the Department of Dermatology and Cosmetology,the Second People's Hospital of Bijie City.The cumulative dose of unilateral face was 20-30 U,and 40-60 U per patient.Clinical erythema score,dermatology life quality index(DLQI),symptom and sign score,and adverse reactions were assessed before and 8 weeks after the treatment.Results All 27 patients completed the study.Patients showed significant improvements in the clinical erythema score(from 2.67±0.83 to 1.30±0.60,t=10.54,P＜0.001),DLQI(from 14.96±5.50 to 6.52±2.79,t=9.38,P＜0.001)8 weeks after the treatment.Similarly,the facial skin burning score,dryness score,itching score,flushing score,and edema score were also significantly de-creased(all P＜0.01 vs.baseline).However,the score of facial capillary dilation did not change significantly(P=0.1).No significant adverse reactions,such as pain,local bruising,facial mus-cle paralysis,or unnatural expressions,were observed.Conclusions Electro-hydrodynamic droplet injection of BTX-A is safe and effective for improving the symptoms such as erythema,burning,dry-ness,itching,flushing and edema,and quality of life in ETR patients.